Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer
Stopped Data collection is completed. As no changes in the endpoints were expected in the future, no further data is needed.
Conditions
Interventions
- BIOLOGICAL: bevacizumab
- OTHER: no maintenance
Sponsor
Swiss Cancer Institute